Novavax (NVAX) said Friday it achieved the first milestone under its agreement with Sanofi (SNY), earning a $50 million payment tied to progress in its phase 2/3 trial for a COVID-19 vaccine in children.
The payment marks the first milestone since the partnership began in May, Novavax said. The company could earn up to $300 million in additional milestones related to its COVID-19 vaccine and a further $350 million for combination products under the agreement, alongside tiered royalties on future sales.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。